Biomarin Share Based Compensation vs Cash Flow Per Share Analysis

BMRN Stock  USD 87.34  1.27  1.43%   
Trend analysis of Biomarin Pharmaceutical balance sheet accounts such as Short Long Term Debt Total of 1.2 B, Other Current Liabilities of 372 M or Total Current Liabilities of 1.2 B provides information on Biomarin Pharmaceutical's total assets, liabilities, and equity, which is the actual value of Biomarin Pharmaceutical to its prevalent stockholders. By breaking down trends over time using Biomarin Pharmaceutical balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

About Biomarin Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Biomarin Pharmaceutical at a specified time, usually calculated after every quarter, six months, or one year. Biomarin Pharmaceutical Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Biomarin Pharmaceutical and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Biomarin currently owns. An asset can also be divided into two categories, current and non-current.

Biomarin Pharmaceutical Balance Sheet Chart

Biomarin Pharmaceutical Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Biomarin Pharmaceutical uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Biomarin Pharmaceutical's Accounts Payable is very stable compared to the past year. As of the 29th of March 2024, Cash is likely to grow to about 792.9 M, while Net Debt is likely to drop about 216.1 M.

Total Assets

Total assets refers to the total amount of Biomarin Pharmaceutical assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Biomarin Pharmaceutical books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Biomarin Pharmaceutical balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Biomarin Pharmaceutical are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.
Most indicators from Biomarin Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biomarin Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.At this time, Biomarin Pharmaceutical's Tax Provision is very stable compared to the past year. As of the 29th of March 2024, Enterprise Value Multiple is likely to grow to 74.10, while Selling General Administrative is likely to drop about 246.1 M.
 2021 2022 2023 2024 (projected)
Gross Profit1.4B1.6B1.8B1.9B
Total Revenue1.8B2.1B2.4B2.5B

Biomarin Pharmaceutical fundamental ratios Correlations

0.950.770.861.00.970.6-0.360.550.740.990.320.690.940.760.690.960.880.980.970.950.970.480.750.560.12
0.950.680.810.920.930.62-0.460.550.820.90.270.830.850.810.770.860.850.940.980.860.960.490.790.670.23
0.770.680.530.810.630.290.26-0.080.620.750.190.410.80.410.470.820.660.650.640.850.76-0.050.40.22-0.07
0.860.810.530.840.850.52-0.370.680.610.820.150.490.890.550.310.890.820.850.850.830.870.380.570.440.33
1.00.920.810.840.960.57-0.290.50.720.980.30.650.960.720.650.970.880.970.940.970.960.430.710.520.08
0.970.930.630.850.960.64-0.540.690.710.960.290.730.90.820.720.910.90.990.970.890.940.60.80.630.12
0.60.620.290.520.570.64-0.490.420.070.640.160.490.490.620.570.530.370.640.650.510.520.630.60.77-0.29
-0.36-0.460.26-0.37-0.29-0.54-0.49-0.85-0.27-0.35-0.08-0.59-0.19-0.66-0.52-0.19-0.35-0.53-0.52-0.17-0.35-0.79-0.64-0.65-0.19
0.550.55-0.080.680.50.690.42-0.850.40.540.260.50.460.620.370.450.560.670.660.410.530.760.630.490.4
0.740.820.620.610.720.710.07-0.270.40.660.250.770.680.650.630.670.80.710.770.690.820.210.640.330.49
0.990.90.750.820.980.960.64-0.350.540.660.40.620.910.750.690.930.840.970.940.930.920.550.740.520.07
0.320.270.190.150.30.290.16-0.080.260.250.40.180.160.390.440.180.210.280.340.250.180.520.37-0.050.39
0.690.830.410.490.650.730.49-0.590.50.770.620.180.530.850.850.540.60.730.790.570.750.50.840.790.17
0.940.850.80.890.960.90.49-0.190.460.680.910.160.530.60.460.990.90.90.870.930.950.260.60.410.13
0.760.810.410.550.720.820.62-0.660.620.650.750.390.850.60.870.60.70.810.830.610.730.690.990.640.16
0.690.770.470.310.650.720.57-0.520.370.630.690.440.850.460.870.480.550.720.760.550.650.650.820.690.0
0.960.860.820.890.970.910.53-0.190.450.670.930.180.540.990.60.480.880.910.880.970.950.260.60.440.09
0.880.850.660.820.880.90.37-0.350.560.80.840.210.60.90.70.550.880.870.860.830.90.310.680.330.27
0.980.940.650.850.970.990.64-0.530.670.710.970.280.730.90.810.720.910.870.980.90.950.590.80.640.12
0.970.980.640.850.940.970.65-0.520.660.770.940.340.790.870.830.760.880.860.980.870.950.60.820.660.23
0.950.860.850.830.970.890.51-0.170.410.690.930.250.570.930.610.550.970.830.90.870.930.290.620.450.07
0.970.960.760.870.960.940.52-0.350.530.820.920.180.750.950.730.650.950.90.950.950.930.360.720.590.19
0.480.49-0.050.380.430.60.63-0.790.760.210.550.520.50.260.690.650.260.310.590.60.290.360.670.580.13
0.750.790.40.570.710.80.6-0.640.630.640.740.370.840.60.990.820.60.680.80.820.620.720.670.620.19
0.560.670.220.440.520.630.77-0.650.490.330.52-0.050.790.410.640.690.440.330.640.660.450.590.580.62-0.16
0.120.23-0.070.330.080.12-0.29-0.190.40.490.070.390.170.130.160.00.090.270.120.230.070.190.130.19-0.16
Click cells to compare fundamentals

Biomarin Pharmaceutical Account Relationship Matchups

Biomarin Pharmaceutical fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets4.7B5.8B6.0B6.4B6.8B7.2B
Short Long Term Debt Total848.1M1.1B1.1B1.1B1.1B1.2B
Other Current Liab(13.0M)289.2M329.4M346.6M354.2M372.0M
Total Current Liabilities932.5M492.5M539.8M588.9M1.2B1.2B
Total Stockholder Equity3.1B4.1B4.3B4.6B5.0B5.2B
Property Plant And Equipment Net1.0B1.0B1.0B1.1B1.1B1.2B
Net Debt410.7M426.0M491.8M358.5M378.7M216.1M
Retained Earnings(1.7B)(861.6M)(925.7M)(789.2M)(621.6M)(652.6M)
Accounts Payable570.6M191.4M193.0M231.2M315.5M331.3M
Cash437.4M649.2M587.3M724.5M755.1M792.9M
Non Current Assets Total2.7B3.5B3.7B3.6B3.9B4.1B
Non Currrent Assets Other122.0M142.2M151.8M176.2M121.2M72.7M
Cash And Short Term Investments753.8M1.1B1.0B1.3B1.1B595.1M
Net Receivables377.4M448.4M373.4M461.3M633.7M665.4M
Common Stock Shares Outstanding179.0M191.7M182.9M189.0M191.6M127.6M
Liabilities And Stockholders Equity4.7B5.8B6.0B6.4B6.8B7.2B
Non Current Liabilities Total635.2M1.2B1.2B1.2B713.0M586.6M
Inventory680.3M698.5M776.7M894.1M1.1B1.2B
Other Current Assets130.7M129.9M110.4M104.5M141.4M148.5M
Other Stockholder Equity4.8B5.0B5.2B5.4B5.6B5.9B
Total Liab1.6B1.7B1.7B1.8B1.9B2.0B
Property Plant And Equipment Gross1.0B1.0B1.8B1.9B1.9B2.0B
Total Current Assets1.9B2.3B2.3B2.8B3.0B3.1B
Accumulated Other Comprehensive Income20.2M(16.1M)14.4M(3.9M)(38.6M)(36.7M)
Intangible Assets456.6M417.3M388.7M338.6M294.7M244.4M
Common Stock Total Equity178K180K182K184K211.6K126.8K
Short Term Investments316.4M416.2M426.6M567.0M318.7M276.3M
Common Stock180K182K184K186K189K133.2K
Other Assets612.0M1.6B1.6B1.6B1.8B1.9B
Long Term Debt486.2M1.1B1.1B1.1B593.1M553.3M
Property Plant Equipment1.0B1.0B1.0B1.1B1.3B1.3B
Other Liab98.1M174.3M113.7M73.5M84.5M81.8M
Net Tangible Assets2.5B3.5B3.7B4.1B4.7B4.9B
Retained Earnings Total Equity(1.7B)(1.7B)(861.6M)(925.7M)(833.1M)(874.8M)
Long Term Debt Total830.4M486.2M1.1B1.1B1.2B730.7M
Capital Surpluse4.7B4.8B5.0B5.2B6.0B3.7B
Long Term Investments412.0M285.5M507.8M333.8M611.1M353.3M

Pair Trading with Biomarin Pharmaceutical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

Moving together with Biomarin Stock

  0.64MBRX Moleculin Biotech Financial Report 9th of May 2024 PairCorr
  0.87MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr

Moving against Biomarin Stock

  0.81MGNX MacroGenics Financial Report 14th of May 2024 PairCorr
  0.77EQ Equillium Financial Report 9th of May 2024 PairCorr
  0.76MDWD Mediwound Downward RallyPairCorr
  0.63CLVRW Clever Leaves HoldingsPairCorr
The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.
The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Complementary Tools for Biomarin Stock analysis

When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Commodity Directory
Find actively traded commodities issued by global exchanges
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Equity Valuation
Check real value of public entities based on technical and fundamental data
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Fundamental Analysis
View fundamental data based on most recent published financial statements
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.98
Earnings Share
0.87
Revenue Per Share
12.88
Quarterly Revenue Growth
0.202
Return On Assets
0.0163
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.